Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Chelsea Therapeutics International, Ltd. (CHTP) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/23/2014 8-K Form 8-K - Current report
05/12/2014 8-K Other Events
05/08/2014 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Chelsea Therapeutics International, Ltd., H. Lundbeck A/S and Charlie Acquisition Corp",
"Form of Contingent Value Rights Agreement",
"Lundbeck to acquire Chelsea Therapeutics"
02/18/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Announces FDA Accelerated Approval of NORTHERA TM for the Treatment of Symptomatic NOH"
02/14/2014 8-K Regulation FD Disclosure
01/30/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer"
01/27/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director"
11/15/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between Chelsea Therapeutics International, Ltd. and JMP Securities LLC, as representative of the several underwriters named therein",
"Opinion of Morgan, Lewis & Bockius LLP",
"CHELSEA THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Charlotte, N.C. – November 12, 2013 – Chelsea Therapeutics International, Ltd. , a development stage pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from this offering to fund its droxidopa program, including regulatory and possible initial commercialization activity for NORTHERA™, ...",
"CHELSEA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Charlotte, N.C. – November 13, 2013 – Chelsea Therapeutics International, Ltd. , a development stage pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products, announced today that it has priced an underwritten public offering of 6,666,667 shares of its common stock at an offering price of $3.00 per share, for total gross proceeds of approximately $20 million. The Company has granted the underwriters a 30-day option to purchase up to 1,000,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on November 18, 2013, subject to customary closing conditions. The Company intends to use the net proceeds ..."
11/05/2013 8-K Termination of a Material Definitive Agreement
10/10/2013 8-K Other Events
10/10/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Announces FDA Advisory Committee to Review NORTHERA™"
07/29/2013 8-K Form 8-K - Current report
06/11/2013 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Certificate of Amendment to Certificate of Incorporation, as amended"
04/19/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chelsea Therapeutics International, Ltd. Executive Severance Plan",
"Chelsea Therapeutics International, Ltd. Executive Retention Bonus Plan"
03/08/2013 8-K Other Events
02/20/2013 8-K Other Events
02/20/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Receives FDA Guidance for a Northera™ NDA Resubmission with Study 306B"
11/26/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Wyrick Robbins Yates & Ponton, LLP",
"Amendment No. 3, to Sales Agreement, between Chelsea Therapeutics International, Ltd. and Cantor Fitzgerald & Co, as amended on July 26, 2011 and December 28, 2011"
10/19/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Severance Agreement between Chelsea Therapeutics International, Ltd. and Mr. Joseph G. Oliveto"
10/17/2012 8-K Other Events
09/10/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "PowerPoint presentation of September 10, 2012"
07/13/2012 8-K Form 8-K - Current report
07/03/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Provides an Update on Northera™ Regulatory Status and Development Program"
06/22/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Combined Northera Data From Two Phase 3 Trials Confirm Symptom Improvement in Patients With Neurogenic OH"
06/12/2012 8-K Submission of Matters to a Vote of Security Holders
06/07/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Chelsea Therapeutics Announces $6 million in Cost Saving Initiatives To Support Expanded Enrollment Initiatives For Northera Study and Extend Cash Runway into Third Quarter 2013"
06/05/2012 8-K Other Events
05/31/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Reports Top-Line Results of Phase II Trial of CH-4051 in Rheumatoid Arthritis"
05/22/2012 8-K Quarterly results
Docs: "Chelsea Therapeutics Completes End-of-Review Meeting with FDA for Northera™ Capsules New Drug Application"
05/04/2012 8-K Other Events
04/10/2012 8-K Form 8-K - Current report
03/06/2012 8-K Quarterly results
Docs: "Chelsea Therapeutics Reports Fourth Quarter and Full Year 2011 Results"
02/24/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Advisory Panel Recommends Approval of Chelsea's NORTHERA™ for the Treatment of Symptomatic Neurogenic OH"
01/11/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Chelsea Therapeutics Announces Exercise of Over-Allotment Option and Completion of the Public Offering of Common Stock"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy